Biomarker discovery by comprehensive phenotyping for autoimmune diseases.
There is a well-recognized but unmet need for biological markers to characterize disease type, status, progression, and response to therapy in autoimmune diseases. We are developing and applying an integrated bioanalytical platform and clinical research program to facilitate comprehensive differential phenotyping of patient samples and enable the discovery of biomarkers. Our measurement platform includes microvolume laser scanning cytometry for the quantification of hundreds of cellular parameters in whole blood and other samples, liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry for the quantification of proteins and low molecular weight biomolecules in serum and other fluids or tissues, and specific immunoassays for the quantification of trace proteins in serum. We describe the technologies and discuss initial applications to the analysis of subjects with rheumatoid arthritis (RA) and healthy controls.
Kantor
Aaron B
AB
SurroMed, Inc., Menlo Park, CA 94025, USA. akantor@surromed.com
Wang
Weixun
W
Lin
Hua
H
Govindarajan
Harini
H
Anderle
Markus
M
Perrone
Andrea
A
Becker
Christopher
C
D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000276:immunology*; D015415:Biomarkers / Q000097:blood*; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D019044:Image Cytometry / Q000379:methods; D017846:Longitudinal Ligaments; D008297:Male; D010641:Phenotype; D040901:Proteomics / Q000379:methods*; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods
D015415:Biomarkers